Endocrine Abstracts

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have highly heterogeneous growth rates, yielding broad ranges of radiographic imaging intervals in standard guidelines, creating uncertainty for clinicians and patients. Chromogranin A (CgA) is released by GEP-NET cells and has been associated with increased tumor burden. However, clinical utility of CgA measurement has been limited by the lack of prospective validation studies and by different sensitivity for...